Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Combines Its Life Sciences and Diagnostics Businesses

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Decision follows Agilent's announcement that it plans to separate the company into two independent publicly traded companies.

Agilent Technologies Inc. announces it has combined its Life Sciences Group with its Diagnostics and Genomics business, naming Lars Holmkvist the new group's president and senior vice president of Agilent, effective immediately. Holmkvist was previously president of the Diagnostics and Genomics Group and senior vice president of Agilent.

The split will see one company focused on life sciences, diagnostics and applied markets, retaining the Agilent name, and the other focused on electronic measurement, which will be named later.

Agilent, the life sciences, diagnostics and applied markets company, will be comprised of two businesses - the Chemical Analysis Group, led by Mike McMullen, current group president and Agilent senior vice president, and the new Life Sciences and Diagnostics Group, under Holmkvist as its president. Nick Roelofs, who has been president of the Life Sciences Group, will leave Agilent to pursue other business opportunities.

"We are creating a new Agilent with a simplified structure that can move quickly to develop and deliver industry-leading total workflow solutions for our customers," said William (Bill) Sullivan, Agilent president and CEO. "Lars is the ideal leader for the new group with his years of experience, depth of market knowledge and superb leadership style."

Agilent also announced that with the spinoff of its electronic measurement business, it has created a new Agilent Order Fulfillment organization. Henrik Ancher-Jensen has been named president of Agilent Order Fulfillment and senior vice president of Agilent. He replaces Gooi Soon Chai, who is joining the electronic measurement spinoff company. Ancher-Jensen was previously vice president, Global Product Supply, for Agilent's Diagnostics and Genomics Group, and corporate vice president, Global Operations, for Dako.

"Henrik understands the priority of customer satisfaction while at the same time contributing to margin expansion goals. His experience and drive for excellence makes him a great match for this important position," Sullivan said.

"The new simplified organization positions an already strong set of businesses for greater growth and shareholder return," Sullivan said.

Lars Holmkvist
Holmkvist joined Agilent in June 2012, when Agilent acquired Dako. He had been president and CEO of Dako since 2009. Before joining Dako, Holmkvist served as president, Europe, for Applied Biosystems, where he was later promoted to president, International, with responsibilities for all commercial operations outside the U.S.

Holmkvist brings more than 25 years' experience within the medical device and pharmaceutical industries, where he has held increasingly significant roles in marketing, sales and business management. He holds a degree in economics from Handelshogskolan Sundsvall in Sweden.

Henrik Ancher-Jensen
Ancher-Jensen came to Agilent in June 2012 with the acquisition of Dako. He joined Dako in 2006 as vice president, Supply Chain, and chief information officer, and was subsequently promoted to corporate vice president, Global Operations. Prior to joining Dako, he spent more than 15 years in senior management roles and management consulting with Chr. Hansen, Deloitte Consulting and NVE. Ancher-Jensen holds a degree in economics from Aarhus University in Denmark.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Reports Third-Quarter Results
Revenues were $1.65 billion for the third fiscal quarter ended July 31, 2013, down 4 percent over one year ago.
Thursday, August 15, 2013
Agilent Technologies Reports Fourth-Quarter 2012 Results
Revenues for the fourth fiscal quarter ended October 31, 2012 were $1.77 billion, up 2 percent one year ago.
Tuesday, November 20, 2012
Scientific News
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!